Solithromycin rejection chills antibiotic sector

The US Food and Drug Administration (FDA) in December rejected the new antibiotic solithromycin over liver toxicity fears, putting the future of the drug in doubt and sending a chill through companies working on novel antimicrobials. “The problems with solithromycin are going to hit the whole sector hard,” says Lloyd Czaplewski, director of Chemical Biology Ventures, a pharmaceutical R&D consultancy in Oxford, UK. “It could put people off getting into an area where we really need some successes.” Read more in Nature Biotechnology.